UK mi­cro­cap faces par­tial clin­i­cal hold in mid-stage IPF tri­al

A tiny UK biotech is work­ing on re­solv­ing a par­tial clin­i­cal hold from the FDA on some co­horts of its mid-stage tri­al, with the com­pa­ny say­ing the de­lay is un­re­lat­ed to clin­i­cal da­ta.

Redx Phar­ma said Thurs­day that US en­roll­ment in­to 12-week co­horts of a Phase IIa study has not been able to get start­ed, al­though there is an open IND in the US. CEO Lisa An­son — re­cruit­ed in 2018 from As­traZeneca, where she served as the Big Phar­ma’s UK pres­i­dent for six years — told End­points News that the FDA is ask­ing for spe­cif­ic da­ta from a study in dogs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER